TICKERNERD
Menu
APVOAPVOHealthcare · Biotechnology

APVO Stock Forecast: Aptevo Therapeutics, Inc. Price Predictions for 2026-2027

Last close, 24 Aug 2026
$2.41
−10.07% on the day

The 1 Wall Street analysts covering Aptevo Therapeutics, Inc. hold a median 12-month price target of $26 — +958.1% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 26 of 100 as at 22 Aug 2026 — in the lower half. The Street sees upside; the factor read is a caution. That gap is the story on this page.

Market cap
$4.8M
Ticker Nerd rank
26 / 100
Median analyst target
$26
Analysts covering
1
Revenue$0.0
Operating income−$6.8M
Net income−$6.7M
Free cash flow−$8.0M
Quarterly, 8 quarters to 31 Mar 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−14.2%
1M
−45.1%
YTD
−74.4%
1Y
−93.2%
From 52W high
−93.2%
From 52W low
0.0%
$2
$36
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

APVO stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Aptevo Therapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 22 Aug 2026
26 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Size
96
Accruals
80
Revisions
64
Volatility
62
Growth
26
Issuance
22
Quality
17
Value
5
Momentum
2

Size (96): Smaller than most of the companies we track.

Momentum (2): The shares have been drifting down relative to others.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

APVO stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on APVO, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0$10$20$30$40Oct 25Jan 26Apr 26Jul 26APVOHigh $30Median $26Low $21

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says1 analysts
1 Buy0 Hold0 Sell
Low $21Median $26High $30

The green dot is the last close — the median target sits +958.1% from it.

Recent analyst actionsNewest first

Of the 9 most recent actions, 1 moved their price target up and 3 moved it down.

DateFirmActionRatingTarget
23 Sept 2024Roth MKMMaintainsBuy$15 → $8.00
13 May 2022Piper SandlerMaintainsOverweight$69 → $20
28 May 2021Roth CapitalMaintainsBuy$64 → $50
25 Nov 2020PiperJaffrayInitiatesOverweight—
25 Nov 2020Roth CapitalInitiatesBuy—
11 Nov 2020Piper SandlerMaintainsOverweight$32 → $69
11 Apr 2018Roth CapitalInitiatesBuy—
9 Sept 2016Piper SandlerInitiatesOverweight—
9 Sept 2016PiperJaffrayInitiatesOverweight—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. APVO appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

APVO vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 24 Aug 2026, Aptevo Therapeutics, Inc. returned −93.2% against +19.6% for the S&P 500, dividends included.

APVO vs S&P 500, last 12 monthsTotal return, rebased to 100
020406080100120Oct 25Jan 26Apr 26Jul 26APVOS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

APVO analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
0
Analysts cutting
1
Fundamentals

Aptevo Therapeutics, Inc. (APVO) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
0.0×

Cheaper than 75% of US stocks

Price / sales
—
Price / book
0.2×

Cheaper than 90% of US stocks

EV / EBITDA
0.0×

Cheaper than 60% of US stocks

Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
—
Operating margin
0.0%

Higher than 32% of US stocks

Net margin
0.0%

Higher than 30% of US stocks

Returns & dividend
Return on equity
−420.3%

Higher than 4% of US stocks

Return on assets
−111.5%

Higher than 2% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Aptevo Therapeutics, Inc. (APVO) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Aptevo Therapeutics, Inc. has a market value of $4.8M and an enterprise value of −$759K.

  • Revenue in the twelve months to 31 Mar 2026: $0.0.

  • Net income over the same four quarters: −$26.3M.

  • Free cash flow in the twelve months to 31 Mar 2026: −$27.0M.

  • Shares outstanding: 1.2M.

  • Trailing P/E: 0.0×; forward P/E: −0.3× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Aptevo Therapeutics, Inc. employs 33 people.

Statement figures: company filings via Twelve Data, four quarters to 31 Mar 2026 · market figures as at 24 Aug 2026

Data provided by Twelve Data

Peers

APVO vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
APVOAptevo Therapeutics, Inc.$4.8M
26
JUNSJupiter Neurosciences, Inc.$4.8M
11
GOVXGeoVax Labs, Inc.$4.8M
29
VIVSVivoSim Labs, Inc.$4.7M
30
MLECMoolec Science SA$5.1M
3
GLMDGalmed Pharmaceuticals Ltd.$4.5M
19
JAGXJaguar Health, Inc.$4.5M
57

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Aptevo Therapeutics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest APVO news & analysis

Aptevo Provides 2Q26 Business Update and Reports Second Quarter Financial Results

Accesswire · 14 Aug 2026positive

Aptevo Therapeutics reported its second-quarter 2026 financial results and provided a business update. The update highlighted strong clinical progress for mipletamig, including data in frontline acute myeloid leukemia and a path toward Phase 2, the appointment of a Chief Scientific Officer, non-dilutive grant funding advancing its trispecific pipeline, and a 50/50 collaboration with Niowave to pursue radiopharmaceutical therapeutic development.

Why it matters — APVO watchers would note the combination of advancing clinical data, strengthened leadership, non-dilutive funding, and a new partnership as signals of pipeline progress across multiple therapeutic areas.

Aptevo Therapeutics Announces Closing of Existing Warrants Exercise and PIPE for $4.5 Million Gross Proceeds

Accesswire · 13 Aug 2026neutral

Aptevo Therapeutics closed a warrant inducement transaction in which holders of its existing common warrants exercised in full for cash to purchase up to 254,922 shares at a reduced exercise price of $4.03 per share, generating approximately $4.5 million in gross proceeds. In exchange, the company issued new unregistered Inducement Warrants to purchase up to 1,274,610 shares at the same exercise price.

Why it matters — APVO watchers would note that the company raised approximately $4.5 million in gross proceeds while issuing additional warrants that could lead to future dilution.

Aptevo Therapeutics Announces Exercise of Existing Warrants and PIPE for $4.5 Million Gross Proceeds

Accesswire · 12 Aug 2026neutral

Aptevo Therapeutics announced it entered into warrant inducement agreements with existing warrant holders to exercise their warrants for cash, generating approximately $4.5 million in gross proceeds, and in exchange issued new inducement warrants at a reduced exercise price of $4.03 per share.

Why it matters — The exercise of existing warrants and issuance of new inducement warrants provides the company with additional capital while also potentially diluting existing shareholders.

Aptevo Strengthens Solid Tumor Strategy with Patent Filing for Nectin-4 x PD-L1 Dual Targeting Backbone

Accesswire · 27 July 2026positive

Aptevo Therapeutics announced a new solid tumor strategy and filed a patent application covering a proprietary Nectin-4 x PD-L1 dual-targeting backbone designed to support multiple therapeutic approaches, including radiopharmaceuticals and T-cell engagers.

Why it matters — The patent filing signals a broadening of Aptevo's oncology pipeline through a versatile platform that could open up new partnering opportunities and therapeutic avenues.

FAQ

Frequently asked questions about APVO stock

What is the APVO stock price forecast for 2026-2027?

The 1 Wall Street analysts covering Aptevo Therapeutics, Inc. have a median 12-month price target of $26, with estimates ranging from $21 to $30. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is APVO stock a buy right now?

Of the 1 analysts covering Aptevo Therapeutics, Inc., 1 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Aptevo Therapeutics, Inc. 26 out of 100 across roughly 4,600 US stocks as at 22 Aug 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank APVO?

As at 22 Aug 2026, Aptevo Therapeutics, Inc. ranks 26 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (96 of 100).

Will APVO stock go up?

No one can know that. What the data says: the median 12-month target from 1 analysts implies +958.1% from the last close, and Ticker Nerd's factor model ranks Aptevo Therapeutics, Inc. 26 out of 100 as at 22 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the APVO stock forecast for 2030?

No analyst covering Aptevo Therapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for APVO are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $21 to $30 over the next 12 months.

How has APVO stock performed over the past year?

Aptevo Therapeutics, Inc. returned -93.2% over the 12 months to 24 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Aptevo Therapeutics, Inc. do?

Aptevo Therapeutics Inc. is a clinical-stage biotechnology company focused on developing novel bispecific and trispecific immunotherapies for cancer treatment.

What is the latest news on APVO?

The most recent item we track (Accesswire, 14 Aug 2026): "Aptevo Provides 2Q26 Business Update and Reports Second Quarter Financial Results". Aptevo Therapeutics reported its second-quarter 2026 financial results and provided a business update. The update highlighted strong clinical progress for mipletamig, including data in frontline acute myeloid leukemia and a path toward Phase 2, the appointment of a Chief Scientific Officer, non-dilutive grant funding advancing its trispecific pipeline, and a 50/50 collaboration with Niowave to pursue radiopharmaceutical therapeutic development.

Company

About Aptevo Therapeutics, Inc.

Aptevo Therapeutics Inc. is a clinical-stage biotechnology company focused on developing novel bispecific and trispecific immunotherapies for cancer treatment. Its lead candidate, mipletamig (CD123 x CD3), is a T-cell engager evaluated in the Phase 1b/2 RAINIER trial for frontline acute myeloid leukemia, combined with standard therapies, showing promising remission rates and a favorable safety profile without cytokine release syndrome in frontline patients. The pipeline includes eight candidates, such as ALG.APV-527 targeting co-stimulatory receptors and tumor antigens, APVO442 (PSMA x CD3) for prostate cancer, APVO455 (Nectin-4 x CD3) for solid tumors, and trispecifics APVO451 and APVO452 that engage tumor antigens, CD3 for T-cell activation, and CD40 for immune modulation. These are generated using the proprietary ADAPTIR and ADAPTIR-FLEX modular protein technology platforms, designed to enhance immune responses against hematologic malignancies and solid tumors. Founded in 2016 and headquartered in Seattle, Washington, Aptevo Therapeutics Inc. operates in the immuno-oncology and hematology sectors, advancing next-generation T-cell engagers to address unmet needs in cancer care.

CEO Mr. Jeffrey G. Lamothe CA · 33 employees · United States · https://aptevotherapeutics.com